In determining whether a higher dose of folic acid supplementation is warranted, a woman's health care provider should first ascertain whether the woman has personal characteristics or health conditions associated with an elevated risk of having a baby with a NTD.
After this is established, the health care provider should assess whether the elevated risk is related to a woman's:
Risk factors for a NTD associated with low dietary intakes of folate (in the absence of elevated folate requirements)Footnote 1:
Risk factors for a NTD that may be associated with elevated folate requirementsFootnote 1:
Risk factors for a NTD in which it is uncertain whether altered folate metabolism (and specifically an elevated folate requirement) plays a role in the etiology of the birth defectFootnote 5,Footnote 6,Footnote 7,Footnote 8,Footnote 9,Footnote 10:
If the indicator of risk for a NTD is associated with low dietary folate intake (situation A), in the absence of an elevated requirement, it is not necessary to advise more than 0.4 mg per day of supplemental folic acid.
If the indicator of a NTD risk is associated with an elevated folate requirement (situation B), a higher dose of folic acid (greater than 0.4 mg/d) should be recommended. However, clear instructions should be given to the woman on when this higher dose should be started, and transitioned to a lower dose supplement or stopped. (See response to question 2 for details on how to provide a higher dose of folic acid.)
In the case of situation C, the health care provider may wish to measure a woman's red blood cell (RBC) folate concentration in order to determine the most appropriate dose of folic acid to recommendFootnote 11. It has been shown that RBC folate concentrations greater than 906 nmol/L are maximally protective against folate-dependent NTDsFootnote 12.
A woman with personal characteristics or health conditions that put her at risk of a pregnancy affected by a neural tube defect (NTD) due to elevated folate requirements (situation B, or in situation C, when RBC folate concentration is less than 906 nmol/L) should consume 4 to 5 mg per day of folic acid in combination with a B12-containing multivitamin supplement. She should be advised to start taking this supplemental dose at least 3 months before conception and to continue until 10 to12 weeks into her pregnancyFootnote 13. At 10 to12 weeks, she can be advised to transition to a daily multivitamin supplement containing 0.4 mg of folic acid for the duration of pregnancy and lactation.
If it is determined that a woman may benefit from a higher level of supplemental folic acid, a health care provider can recommend that a woman:
With both approaches, the multivitamin supplement should contain vitamin B12; most multivitamin supplements available in Canada contain vitamin B12.
Women should be advised not to take more than one multivitamin supplement each day in an attempt to consume a higher dose of supplemental folic acid. In large doses some substances in multivitamins could be harmful. This is especially true of Vitamin A in the retinol form (including retinyl palmitate and retinyl acetate). The Tolerable Upper Intake Level (UL) for vitamin A is 3,000 mcg retinol activity equivalent (RAE) or 10,000 IU.
In the event that a woman doesn't conceive after 3 or 4 months and adherence in taking supplements daily is good, a lower level of folic acid supplementation (0.4 to1.0 mg) should be considered. By this time, the blood folate concentrations of most women will be within the maximally protective rangeFootnote 14. Red blood cell (RBC) folate concentrations should be determined after 4 months on a lower dose of folic acid. Her RBC folate concentration will decrease, but it is important to ensure it remains above 906 nmol/L to provide maximal protection against NTDsFootnote 12. The health care provider should have the woman re-tested after an additional 4 months to confirm that a new plateau for RBC folate concentration above 906 nmol/L has been achieved.
Again, in this instance, the woman's red blood cell (RBC) folate concentration can be used to guide the most appropriate dose of folic acid to recommendFootnote 11. It has been shown that RBC folate concentrations above 906 nmol/L are maximally protective against folate-dependent NTDsFootnote 12.
Women should be advised not to take more than one multivitamin supplement each day in an attempt to consume a higher dose of supplemental folic acid. In large doses some substances in multivitamins could be harmful. This is especially true of Vitamin A in the retinol form (including retinyl palmitate and retinyl acetate). The Tolerable Upper Intake Level (UL) for vitamin A is 3,000 mcg retinol activity equivalent (RAE) or 10,000 IU.
Institute of Medicine. Food and Nutrition Board. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin b6, folate, vitamin b12, pantothenic acid, biotin, and choline. Washington, DC: National Academy Press 1998.
Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343(22): 1608-14.
Ornoy A. Neuroteratogens in man: An overview with special emphasis on the teratogenicity of antiepileptic drugs in pregnancy. Reprod Toxicol 2006; 22(2): 214-26.
Gasteyger C, Suter M, Gaillard RC, Giusti V. Nutritional deficiencies after roux-en-y gastric bypass for morbid obesity often cannot be prevented by standard multivitamin supplementation. Am J Clin Nutr 2008; 87(5): 1128-33.
Rasmussen SA, Chu SY, Kim SY, Schmid CH, Lau J. Maternal obesity and risk of neural tube defects: A meta-analysis. Am J Obstet Gynecol 2008; 198(6): 611-9.
Ray JG, Wyatt PR, Vermeulen MJ, Meier C, Cole DE. Greater maternal weight and the ongoing risk of neural tube defects after folic acid flour fortification. Obstet Gynecol 2005; 105(2): 261-5.
Stothard KJ, Tennant PW, Bell R, Rankin J. Maternal overweight and obesity and the risk of congenital anomalies: A systematic review and meta-analysis. JAMA 2009; 301(6): 636-50.
Shaw GM, Velie EM, Schaffer D. Risk of neural tube defect-affected pregnancies among obese women. JAMA 1996; 275(14): 1093-6.
Watkins ML, Rasmussen SA, Honein MA, Botto LD, Moore CA. Maternal obesity and risk for birth defects. Pediatrics 2003; 111(5 Part 2): 1152-8.
Werler MM, Louik C, Shapiro S, Mitchell AA. Prepregnant weight in relation to risk of neural tube defects. JAMA 1996; 275(14): 1089-92.
Tam C, McKenna K, Ingrid Goh Y, Klieger-Grossman C, O'Connor D L, Einarson A, Koren G. Periconceptional folic acid supplementation: A new indication for therapeutic drug monitoring. Ther Drug Monit 2009;31(3):319-26.
Daly LE, Kirke PN, Molloy A, Weir DG, Scott JM. Folate levels and neural tube defects. Implications for prevention. JAMA 1995; 274(21): 1698-702.
Prevention of neural tube defects: Results of the medical research council vitamin study. Mrc vitamin study research group. Lancet 1991; 338(8760): 131-7.
Nguyen P, Tam C, O'Connor DL, Kapur B, Koren G. Steady state folate concentrations achieved with 5 compared with 1.1 mg folic acid supplementation among women of childbearing age. Am J Clin Nutr 2009; 89(3): 844-52.
These questions and answers for health professionals were prepared by:
Additional expert advice was provided by:
Members of the Expert Advisory Group on National Nutrition Pregnancy Guidelines also contributed to this work.